Hypertension — A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)
Citation(s)
A Phase III, Randomized, Active-comparator Controlled and a Long-term Clinical Trial to Study the Safety of MK-0954A (L100/H12.5 mg) in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®]